TCRT alaunos.com: Enterprise Value to EBITDA Ratio

alaunos.com (TCRT) - corporate logo

The daily price chart for Alaunos Therapeutics (TCRT) shows an EV/EBITDA ratio of 0.00, driven by US trade restrictions on high-tech exports to Asia and stringent biosafety regulations. Current volatility stems from a revision of scientific strategies independent of market cycles. Meanwhile, the business relies on streamlined cryogenic logistics for biomaterials, ensuring process stability and future profitability.

Alaunos Therapeutics, Inc. - TCRT Enterprise Value to EBITDA Ratio (period 11/23/2025 - 11/12/2026)

alaunos.com (TCRT) - metric breakdowns and financial figures

- stock price and consensus target price:
Stock Quotes Alaunos Therapeutics, Inc.|TCRT - Average Forecast Price
- company stock capitalization data:
Market Valuation Alaunos Therapeutics, Inc.|TCRT - Value Adjusted for Debt and Cash
- business book valuation details:
Book Value per Share Alaunos Therapeutics|TCRT - Company Net Assets|Market Capitalization to Book Value Ratio alaunos.com|TCRT - Company Assets
- debt and solvency information:
Debt to Equity Alaunos Therapeutics|TCRT - Long-Term Debt to Equity|Short-Term Debt to Equity Alaunos Therapeutics, Inc.|TCRT - Company Debts|Debt to Book Value Alaunos Therapeutics, Inc.|TCRT - Company Long-Term Loans and Borrowings|Company Short-Term Debts Alaunos Therapeutics|Quick Ratio alaunos.com
- financial results and valuation multiples details:
TCRT - Company Net Income|Expected Profit Alaunos Therapeutics|TCRT - Price to Earnings Multiple|Forward P/E Multiple Alaunos Therapeutics, Inc.|TCRT - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Alaunos Therapeutics, Inc.|TCRT - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Alaunos Therapeutics|TCRT - Earnings per share for the last four quarters|Quarterly EPS earnings growth alaunos.com|TCRT - Earnings per share increase in current year|Earnings growth forecast for next year Alaunos Therapeutics
Summary company analytics:Alaunos (TCRT)
Original product of Alaunos Therapeutics, Inc.

Alaunos Therapeutics (TCRT) leverages the robust R&D potential of leading biochemists, which minimizes personnel risks during immunotherapy development. Analyzing this EV/EBITDA multiple chart, an investor can see the ratio of the company's total value (market capitalization and debt) to its operating profit before interest and taxes. This indicator allows for a real-time assessment of the asset's actual value accounting for debt load, determining the efficiency of investments in the high-tech sector.

Key competitors

Legend Biotech Inc. - Enterprise Value to EBITDA Ratio|Sana Corp (SANA) - Company Value to EBITDA|AUTL: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ALLO (allogene.com)|RNAC: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Cellectis|CRBU (Caribou Bio) - EV/EBITDA Multiple|Company Value to EBITDA Instil Bio Inc TIL|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Genenta Science S.p.A. (GNTA)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization IPSC (centurytx.com)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Jasper Therapeutics, Inc. JSPR|Senti Bio - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ADAP: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation CERO (CERo Therapeutics)|ACHL: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple cargo-tx.com CRGX|PSTX (Poseida Therapeutics, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA 2seventy bio Inc. TSVT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Gracell Biotechnologies Ltd (GRCL)